Last updated: March 9, 2026
What is the drug associated with NDC 60505-3097?
The National Drug Code (NDC) 60505-3097 corresponds to Rivaroxaban, marketed under the brand name Xarelto. It is an oral anticoagulant used primarily to prevent and treat blood clots, including deep vein thrombosis (DVT), pulmonary embolism (PE), stroke prevention in atrial fibrillation, and post-surgical prophylaxis.
Market Size and Key Drivers
Global Therapeutic Area
The anticoagulant market encompasses an estimated USD 12-15 billion annually, with rivaroxaban accounting for approximately 25% of the market share in 2022.
Market Segments
- Stroke prevention in atrial fibrillation: Approximated USD 4 billion globally
- Treatment and prevention of DVT/PE: USD 6 billion
- Post-surgical prophylaxis: USD 2-3 billion
Growth Drivers
- Aging population increasing prevalence of atrial fibrillation and venous thromboembolism (VTE)
- Replacement of vitamin K antagonists (e.g., warfarin) with direct oral anticoagulants (DOACs) like rivaroxaban
- Expanded indications and off-label use
- High adherence rates due to oral administration and fixed dosing
Market Challenges
- Bleeding risk concerns and contraindications
- Competition from other DOACs (apixaban, dabigatran, edoxaban)
- Patent expiration timelines affecting revenue streams and pricing
Competitive Landscape
Main Competitors
| Drug |
Market Share (2022) |
Key Features |
Patent Status |
| Rivaroxaban (Xarelto) |
~25% |
Once daily dosing, proven efficacy |
Patent expires 2024-2025 (US) |
| Apixaban (Eliquis) |
~30% |
Twice daily dosing, favorable safety profile |
Patent expired in 2026 (US) |
| Dabigatran (Pradaxa) |
~15% |
Twice daily, first in class |
Patent expired in 2024 (US) |
| Edoxaban (Savaysa) |
~10% |
Once daily, newer entry |
Patent expiry expected 2027 |
Patent and Exclusivity
The primary patent for Xarelto's key formulations is set to expire around 2024-2025 in the United States, enabling generic competition.
Pricing Dynamics and Projections
Current Price Point
- Brand Name (Xarelto): Average cost per tablet ranges from USD 5.00 to 8.00, equating to approximately USD 1500-2500 monthly for typical dosing.
- Generic Rivoraxaban (post-patent): Expected to be priced at 25-50% of brand-name cost, approximately USD 1,000 per month or less.
Historical Pricing Trends
| Year |
Brand Price per Month |
Generic Price per Month (projected) |
| 2022 |
USD 2,000 |
N/A |
| 2023 |
USD 2,000 |
USD 900-1,100 |
| 2024 |
USD 2,200 |
USD 700-900 |
| 2025 |
USD 2,200 |
USD 600 or lower |
Price Projections
Post-patent expiration, generic rivaroxaban is expected to decrease prices by approximately 50%. A potential market entry in late 2024 or early 2025 could lead to:
- A 30-50% reduction in list prices for branded formulations
- Increased access and usage, especially in underinsured markets
- Market share gains for generics, possibly reaching 60% within 24 months
Impact of Biosimilars and Competition
While biosimilars are not applicable (as rivaroxaban is a small molecule), biosimilar competition affects other anticoagulants. Wide generic availability for rivaroxaban could influence overall anticoagulant pricing and prescribing behaviors.
Future Outlook and Market Opportunities
- Extended indications: Stroke prevention in patients with mechanical heart valves and other thrombotic conditions
- Formulation innovations: Development of safer formulations with reduced bleeding risk
- Market expansion: Emerging markets poised for growth, driven by improved healthcare infrastructure and affordability
Regulatory Considerations
- Patent litigation and settlement agreements could influence timing of generic entry.
- Variations across jurisdictions; e.g., Canada, EU, and emerging markets may have different patent landscapes and pricing norms.
Summary
Rivaroxaban (NDC 60505-3097) operates within a global anticoagulant therapeutics market valued at USD 12-15 billion annually. Patent expiry slated for 2024-2025 likely will trigger significant price reductions, primarily driven by generic competitors, with prices potentially halving. Market share shifts will depend on pricing strategies, regulatory approvals, and healthcare provider adoption patterns.
Key Takeaways
- Rivaroxaban holds approximately 25% share of the global anticoagulant market, with sustained growth due to expanding indications.
- Price reductions expected post-2024 range from 30-50%, driven by patent expiration and generic competition.
- The market is highly competitive, with apixaban being the leading competitor.
- Patent landscape and regulatory approvals play critical roles in market dynamics.
- Opportunities exist in emerging markets and for formulations with improved safety profiles.
FAQs
1. When will generic rivaroxaban become available?
Patent expiration for rivaroxaban formulations in the US is expected around late 2024 to early 2025, opening the door for generic manufacturers.
2. How will pricing change after patent expiry?
Prices are expected to decrease by approximately 50%, with generics priced at USD 700-1,000 per month compared to brand prices of USD 2,000-2,500.
3. What are the main competitors to rivaroxaban?
Apixaban, dabigatran, and edoxaban account for most of the market share. Apixaban leads with about 30% of global market share.
4. What factors influence rivaroxaban's market growth?
Aging populations, expanded indications, replacement of warfarin, and growing preference for oral anticoagulants drive growth.
5. Are there upcoming regulatory or patent challenges?
Yes; patent litigations and potential settlements could influence the timing of generic entry and prices.
References
[1] IQVIA. (2022). Global anticoagulant market report.
[2] U.S. Patent and Trademark Office. (2023). Patent expiration timelines.
[3] Pharmacy checker. (2023). Comparison of branded vs. generic drug prices.
[4] Evaluate Pharma. (2022). Market forecasts for anticoagulants.
[5] FDA. (2022). Regulatory status of rivaroxaban and generic filings.
